LEADER 00000nam 2200373 a 4500
001 AH21639446
003 StDuBDS
005 20111202104146.0
007 cr||||||||||||
008 110217s2011 enka sb 001 0 eng d
020 9781444342543|q(e-book)
040 DNLM/DLC|cDLC|dUk|dStDuBDSZ|dUkPrAHLS
050 0 RC862.I53|bC553 2011
082 00 616.344|222
245 00 Clinical dilemmas in inflammatory bowel disease
|h[electronic resource] :|bnew challenges /|cedited by
Peter M. Irving ... [et al.].
250 2nd ed.
260 Chichester :|bWiley-Blackwell,|c2011.
300 xv, 268 p. :|bill.
505 0 Contents: List of Contributors. Preface. Part 1: Genes and
Phenotype in IBD. 1 Which will take us further in IBD -
study of coding variation or epigenetics? ( Miles Parkes
). 2 IBD in different ethnic groups: same or different? (
Rupert W.L. Leong, Dorothy K.L. Chow and Christian P.
Selinger ). Part 2: Bugs and IBD - good, bad or
indifferent? 3 How does the risk of infection influence
management of IBD around the world? ( Kiran K. Peddi and
Ian Craig Lawrance ). 4 Travelling with IBD ( Ing Shian
Soon and Gilaad Kaplan ). 5 What to do about hepatitis B
and hepatitis C in patients with IBD ( Morven Cunningham
and Graham R. Foster ). 6 CMV in IBD - passenger or
pathogen? ( Ahmed Kandiel & Bret Lashner ). 7 Clostridium
difficile in IBD: Impact, Prevention and Treatment (
Ashwin N. Ananthakrishnan and David G. Binion ). 8 Pre-
and synbiotics: placebo or panacea ( James O. Lindsay ). 9
Worms - light at the end of their burrow? ( John Leung and
Joel V. Weinstock ). 10 Do we really need to vaccinate all
patients with IBD? ( Gauree Gupta and Gil Y. Melmed ).
Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or
marvel? ( Richard B. Gearry, Andrew S. Day ). 12 Radiation
exposure in IBD: how do we minimize the dangers? ( Owen J
O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M.
Maher ). 13 Surveillance colonoscopy in UC - what's the
best way to do it? ( Matt Rutter ). Part 4: Medical
therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride
forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? (
Richard Logan and Venkataraman Subramanian ). 16 Why do we
still use 5-ASAs in Crohns disease? ( Stephen Hanauer,
Henit Yanai, Emma Calabrese ). Steroids. 17 Steroids in
Crohn's disease: do the benefits outweigh the dangers? (
A. Hillary Steinhart ). Immunomodulators. 18 Thioguanine
nucleotide measurement: Non-adherent, shunter, under-dosed
or resistant? ( Miles Sparrow ). 19 Thiopurines and the
sun: what should be done? ( Conal M. Perrett, Jane M.
McGregor, Catherine A. Harwood ). 20 Do thiopurines worsen
risk and prognosis of cervical neoplasia? ( Jeremy D.
Sanderson and Melissa A. Smith ). 21 Optimising use of
methotrexate ( Anna Foley and Peter R. Gibson ). 22 Which
calcineurin inhibitor and when? ( A. Barney Hawthorne ).
Biologics. 23 Are all anti-TNF agents the same? ( Jennifer
L. Jones ). 24 One drug or two: Do patients on biologics
need concurrent immunomodulation? ( Glen A. Doherty and
Adam S. Cheifetz ). 25 How do we identify patients needing
early aggressive therapy and what should we use? ( Marc
Ferrante and Severine Vermeire ). 26 What is the role of
biologics in UC? ( Joanna K. Law and Brian Bressler ). 27
What can we do with Crohn's patients refractory to antiTNF
therapy? ( David T. Rubin ). 28 Which EIMs respond to
biologics? ( Tina A. Mehta and CS Probert ). 29 Use and
abuse of biologics in pregnancy ( Marla C. Dubinsky ). 30
Is anti-TNF therapy safe to use in people with a history
of malignancy? ( Mark Lust and Simon Travis ). 31 What and
how should we tell patients about the risks of
immunomodulators and biologics? ( Corey A Siegel ). 32
When, how and in whom should we stop biologics? ( Edouard
Louis, Jacques Belaiche, Catherine Reenaers ). Part 5:
Other treatments. 33 Avoiding drug interactions ( Tim
Elliott and Peter M. Irving ). 34 Is there still a role
for ursodeoxycholic acid treatment in patients with
inflammatory bowel disease associated with primary
sclerosing cholangitis? ( Emmanouil Sinakos & Keith Lindor
). 35 Stem cell transplantation for Crohn's: what's the
risk-benefit ratio? ( Venkataraman Subramanian and
Christopher J Hawkey ). 36 Complementary Therapy: Is There
a Needle in the Haystack? ( Shane M. Devlin ). Part 6:
Surgical Dilemmas in IBD. 37 Optimising IBD patients for
surgery and recovery ( Jonathan Wilson and Alastair
Windsor ). 38 Is surgery the best initial treatment for
limited ileocaecal Crohn's disease? ( Tom Oresland ). 39
Laparoscopic or open surgery for IBD? ( Donna Appleton and
Michael Hershman ). 40 Perianal Crohn's disease - optimal
management ( David A. Schwartz and Norman R. Clark III ).
41 Does anti-TNF therapy increase the risk of
Complications of surgery? ( Ming Valerie Lin, Wojciech
Blonski and Gary R. Lichtenstein ). 42 Pouches for
Indeterminate Colitis and Crohn's Disease: Act Now, Pay
Later? ( Phillip Fleshner ). 43 Dealing with pouchitis (
Bo Shen and Simon McLaughlin ). Part 7: Unsolved issues in
IBD. 44 Mucosal healing in IBD - does it matter? ( Geert
D'Haens ). 45 Vitamin D in IBD: from genetics to bone
health via cancer and immunology ( Helen M. Pappa and
Richard J. Grand ). 46 Got Milk? Medication Use and
Nursing in Women with IBD (Sunanda Kane). 47 Does stress
matter? ( Robert Maunder ). 48 IBS is common in IBD: fact
or fallacy? ( James Goodhand & David Rampton ). 49 So
where is all the cancer? ( Judith E. Baars & C. Janneke
van der Woude ). Part 8: Nutrition in IBD. 50 What should
patients with IBD eat? ( Emile Richman, Keith Leiper,
Jonathan Rhodes ). 51 Enteral Nutrition in Crohn's - Who
for, When, How and Which Formula? ( R. Shamir and Ernest
G. Seidman ). 52 Optimizing treatment of iron deficiency
anemia ( Hermann Schulze and Axel Dignass ). Part 9:
Management process. 53 IBD Standards: will they enhance
patient care? ( Michael D. Kappelman ). 54 Your treatment
won't work if the patient doesn't take it ( Rob Horne ).
55 Inflammatory Bowel Disease: What to tell your ED team (
Louise Langmead ). 56 Transitioning from pediatric to
adult care ( Elizabeth J. Hait and Laurie N. Fishman ). 57
Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD)
Care ( William J. Tremaine ).
506 1 400 annual accesses.|5UkHlHU
650 0 Inflammatory bowel diseases.
650 0 Inflammatory bowel diseases|xDecision making.
700 1 Irving, Peter,|d1970-
856 40 |uhttps://www.vlebooks.com/vleweb/product/
openreader?id=Hull&isbn=9781444342543|zGo to ebook
936 Askews
